Nucleic Acids and Methods for Detecting Chromosomal Abnormalities
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,465,245 | Nucleic Acids and Methods for Detecting Chromosomal Abnormalities In force · High confidence UsedRemaining | Biora Therapeutics, Inc. | In force | High confidence | ||
| US 10,947,595 | Nucleic Acids and Methods for Detecting Chromosomal Abnormalities Lapsed Mar 16, 2025 on the fee record Low confidence | Biora Therapeutics, Inc. | Lapsed Mar 16, 2025 on the fee record | Low confidence | ||
| Application 16/596,118 | Nucleic Acids and Methods for Detecting Chromosomal Abnormalities Abandoned Abandoned Feb 22, 2024 | Biora Therapeutics, Inc. | Abandoned | Abandoned Feb 22, 2024 |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Biora Therapeutics, Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.